For these reasons, the identification of additional predictors to optimize the clinical efficacy of HSP90 inhibitors in lung adenocarcinoma is essential and forms the main objective of the research outcomes reported here. This evidence concerns the gene HSP90AB1 and lung adenocarcinoma.